IP Library Granted Patent US 10,221,399
Granted Patent B2
US 10,221,399 · App. 15/449,827 · Granted Mar 5, 2019

In vitro reconstituted plant virus capsids for delivering RNA genes to mammalian cells

Inventors: William M. Gelbart (Los Angeles, CA); Charles M. Knobler (Los Angeles, CA); Rees F. Garmann (Santa Cruz, CA); Odisse Azizgolshani (Whittier, CA); Ruben D. Cadena-Nava (Ensenada, MX)
Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
C12N7/00C07K14/005C12N7/045C12N9/1247C12Y207/07006C12N2770/14022C12N2770/14023C12N2770/14033C12N2770/14042
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,221,399
App. No.
15/449,827
Granted
Mar 5, 2019
Kind
B2
Abstract

The invention provides compositions of matter comprising a cowpea chlorotic mottle virus capsid protein (CCMV CP) and a ribonucleic acid, as well as methods for using such compositions. In such compositions, the cowpea chlorotic mottle virus capsid protein envelops the ribonucleic acid so as to for a capsid that can inhibit the degradation of the ribonucleic acid (e.g. by RNAses). A method of delivering a ribonucleic acid into the cytoplasm of a mammalian cell is also provided. Typically, the method comprises the steps of combining the mammalian cell with a composition of matter described herein under conditions selected to allow the cowpea chlorotic mottle virus capsid to contact the mammalian cell and deliver the ribonucleic acid into the cytoplasm of a mammalian cell.

Claims (45)

1. A composition of matter comprising:

cowpea chlorotic mottle virus capsid proteins; and

ribonucleic acid; wherein:

the ribonucleic acid is at least 100 nucleotides in length;

the ribonucleic acid is not a cowpea chlorotic mottle virus ribonucleic acid;

relative amounts of cowpea chlorotic mottle virus capsid protein and ribonucleic acid are such that there are at least 10 cowpea chlorotic mottle virus capsid proteins for every 100 nucleotides of ribonucleic acid length; and

the cowpea chlorotic mottle virus capsid proteins form a capsid that envelops the ribonucleic acid, thereby inhibiting degradation of the ribonucleic acid.

2. The composition of claim 1 , further comprising a mammalian cell.

3. The composition of claim 1 , wherein the ribonucleic acid:

(a) encodes a RNA-dependent RNA polymerase;

(b) is between 100 and 10,000 nucleotides in length; and/or

(c) comprises at least 1,000 nucleotides, at least 2,000 nucleotides, at least 3,000 nucleotides, at least 4,000 nucleotides, or at least 5,000 nucleotides; and/or

(d) does not include a signal sequence that modulates packaging of the ribonucleic acid by the capsid proteins.

4. The composition of claim 1 , wherein:

the cowpea chlorotic mottle virus capsid protein is coupled to a polypeptide that is not a cowpea chlorotic mottle virus polypeptide; and

the polypeptide binds a molecule expressed on the surface of a mammalian cell.

5. The composition of claim 1 , wherein the capsid envelopes a single ribonucleic acid molecule.

6. The composition of claim 1 , wherein the ribonucleic acid encodes at least one polypeptide that is expressed in a mammalian cell following delivery of the ribonucleic acid into the cytoplasm of the mammalian cell.

7. The composition of claim 1 , wherein the ribonucleic acid encodes a RNA-dependent RNA polymerase.

8. The composition of claim 1 , wherein the ribonucleic acid encodes a polypeptide selected for its ability to facilitate imaging of the mammalian cell.

9. The composition of claim 1 , wherein the ribonucleic acid encodes a polypeptide useful in a therapeutic regimen.

10. A composition of matter comprising:

a mammalian cell;

cowpea chlorotic mottle virus capsid proteins; and

ribonucleic acid; wherein:

the ribonucleic acid is at least 100 nucleotides in length;

the ribonucleic acid is not a cowpea chlorotic mottle virus ribonucleic acid;

the cowpea chlorotic mottle virus capsid proteins form a capsid that envelops the ribonucleic acid, thereby inhibiting degradation of the ribonucleic acid; and

relative amounts of cowpea chlorotic mottle virus capsid protein and ribonucleic acid are such that there are at least 10 cowpea chlorotic mottle virus capsid proteins for every 100 nucleotides of ribonucleic acid length.

11. The composition of claim 10 , wherein relative amounts of cowpea chlorotic mottle virus capsid protein and ribonucleic acid are such that the mass ratio of cowpea chlorotic mottle virus capsid proteins to ribonucleic acids is at least 6:1.

12. The composition of claim 10 , wherein the cowpea chlorotic mottle virus capsid protein is coupled to a polypeptide selected for its ability to bind a molecule expressed on the surface of the mammalian cell.

13. The composition of claim 10 , wherein the ribonucleic acid encodes at least one polypeptide that is expressed in a mammalian cell following delivery of the ribonucleic acid into the cytoplasm of the mammalian cell.

14. The composition of claim 10 , wherein the ribonucleic acid encodes a RNA-dependent RNA polymerase.

15. The composition of claim 10 , wherein the ribonucleic acid encodes a polypeptide selected for its ability to facilitate imaging of the mammalian cell.

16. The composition of claim 10 , wherein the ribonucleic acid encodes a polypeptide useful in a therapeutic regimen.

17. A composition of matter comprising:

cowpea chlorotic mottle virus capsid proteins; and

ribonucleic acid; wherein:

the ribonucleic acid is at least 100 nucleotides in length;

the ribonucleic acid is not a cowpea chlorotic mottle virus ribonucleic acid;

relative amounts of cowpea chlorotic mottle virus capsid protein and ribonucleic acid are such that there are at least 10 cowpea chlorotic mottle virus capsid proteins for every 100 nucleotides of ribonucleic acid length;

the cowpea chlorotic mottle virus capsid proteins form a capsid that envelops the ribonucleic acid, thereby inhibiting degradation of the ribonucleic acid; and

relative amounts of cowpea chlorotic mottle virus capsid protein and ribonucleic acid are such that the mass ratio of cowpea chlorotic mottle virus capsid proteins to ribonucleic acids is at least 6:1.

18. The composition of claim 17 , wherein the ribonucleic acid encodes a polypeptide selected for its ability to facilitate imaging of the mammalian cell.

19. The composition of claim 17 , wherein the ribonucleic acid encodes a polypeptide useful in a therapeutic regimen.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 27, 2021
From: GELBART, WILLIAM M.; KNOBLER, CHARLES M.; GARMANN, REES F.; AZIZGOLSHANI, ODISSE; CADENA-NAVA, RUBEN D.
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 056376/0611 →
Continuity (3)
Division 14540816 · Nov 13, 2014
Provisional Application 61906061 · Nov 19, 2013
Related Publication 20170183635A1 · Jun 29, 2017